Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sample.

Purpose: Immune checkpoint inhibitors (ICIs) have become an indispensable part of clinical practice; however, off-label use of these agents is unknown. We aimed to define the patterns of off-label use of ICIs in a nationwide sample of patients.

Methods: The online database (Reçetem) was retrospectively searched for off-label use cases related to ICIs approved during a 6-month period.